Search
Close this search box.

Sandoz names new CFO, board nominations

ARTICLE | Management Tracks

Plus: McKinsey vet Littlejohns becomes Velsera’s CEO and updates from MBrace, Fibrobiologics, NeoVac and Mithra

By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst 

March 7, 2024 1:18 AM UTC

Sandoz Group AG (SIX:SDZ; Pink:SDZNY) hired Remco Steenbergen as CFO, effective July 1, and nominated Mathai Mammen and Michael Rechsteiner to its board. Steenbergen, who is group CFO of Deutsche Lufthansa AG and a Sandoz board member, succeeds CFO Colin Bond, who will retire on June 30. Mammen is president, chairman and CEO of Fog Pharmaceuticals Inc. and was EVP, pharmaceuticals, R&D at Johnson & Johnson (NYSE:JNJ) for more than five years until February 2023; Rechsteiner is chairman of Swisscom. Sandoz’s shareholders will vote on the company’s board nominations at its annual general meeting on April 30.

Computational biology company Velsera Inc. named Jamie Littlejohns CEO, succeeding interim CEO Hans Cobben, who remains chairman. Littlejohns co-led McKinsey & Co.’s European healthcare & life science private equity practice as one of the consulting company’s partners…